Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Multiple Sclerosis

  Free Subscription


Articles published in Neurology

Retrieve available abstracts of 180 articles:
HTML format
Text format



Single Articles


    December 2017
  1. LOREFICE L, Fenu G, Gerevini S, Frau J, et al
    PML in a person with multiple sclerosis: Is teriflunomide the felon?
    Neurology. 2017 Dec 6. pii: WNL.0000000000004804.
    PubMed     Text format    


  2. FITZGERALD KC, Tyry T, Salter A, Cofield SS, et al
    Diet quality is associated with disability and symptom severity in multiple sclerosis.
    Neurology. 2017 Dec 6. pii: WNL.0000000000004768.
    PubMed     Text format     Abstract available


  3. SUMOWSKI JF, McDonnell GV, Bourdette D
    Diet in multiple sclerosis: Science takes a seat at the table.
    Neurology. 2017 Dec 6. pii: WNL.0000000000004775.
    PubMed     Text format    


    November 2017
  4. KARCESKI S
    How comorbid conditions affect the choice of treatment in multiple sclerosis.
    Neurology. 2017;89:e265-e267.
    PubMed     Text format    


  5. LARONI A, Signori A, Maniscalco GT, Lanzillo R, et al
    Assessing association of comorbidities with treatment choice and persistence in MS: A real-life multicenter study.
    Neurology. 2017;89:2222-2229.
    PubMed     Text format     Abstract available


  6. KOWALEC K, McKay KA, Patten SB, Fisk JD, et al
    Comorbidity increases the risk of relapse in multiple sclerosis: A prospective study.
    Neurology. 2017 Nov 8. pii: 10.1212/WNL.0000000000004716.
    PubMed     Text format     Abstract available


  7. BURMAN J, Zelano J
    Epilepsy in multiple sclerosis: A nationwide population-based register study.
    Neurology. 2017 Nov 8. pii: 10.1212/WNL.0000000000004740.
    PubMed     Text format     Abstract available


  8. ARRAMBIDE G, Tintore M, Auger C, Rio J, et al
    Lesion topographies in multiple sclerosis diagnosis: A reappraisal.
    Neurology. 2017 Nov 3. pii: 10.1212/WNL.0000000000004715.
    PubMed     Text format     Abstract available


    October 2017
  9. NOVAKOVA L, Zetterberg H, Sundstrom P, Axelsson M, et al
    Monitoring disease activity in multiple sclerosis using serum neurofilament light protein.
    Neurology. 2017 Oct 27. pii: 10.1212/WNL.0000000000004683.
    PubMed     Text format     Abstract available


  10. CHIANG S, Kesari NK, Bradshaw A, Chen W, et al
    Pearls & Oy-sters: CNS lymphoma in a patient with relapsing-remitting multiple sclerosis treated with interferon.
    Neurology. 2017;89:e210-e213.
    PubMed     Text format    


  11. TSIVGOULIS G, Papadimitropoulos GN, Katsanos AH, Zompola C, et al
    Teaching NeuroImages: Interferon-induced psoriasis flare in a multiple sclerosis case remits with dimethyl fumarate.
    Neurology. 2017;89:e188-e189.
    PubMed     Text format    


  12. MUNGER KL, Hongell K, Aivo J, Soilu-Hanninen M, et al
    25-Hydroxyvitamin D deficiency and risk of MS among women in the Finnish Maternity Cohort.
    Neurology. 2017;89:1578-1583.
    PubMed     Text format     Abstract available


    September 2017
  13. KARCESKI S
    Multiple sclerosis, inflammation in the brain, and mood.
    Neurology. 2017;89:e169-e171.
    PubMed     Text format    


  14. MARRIE RA, Salter A, Tyry T, Cutter GR, et al
    Author response: High hypothetical interest in physician-assisted death in multiple sclerosis.
    Neurology. 2017;89:1429-1430.
    PubMed     Text format    


  15. SETHI NK
    Letter re: High hypothetical interest in physician-assisted death in multiple sclerosis and Physician-assisted death in chronic neurologic diseases.
    Neurology. 2017;89:1429.
    PubMed     Text format    


  16. MASDEU JC
    Letter re: High hypothetical interest in physician-assisted death in multiple sclerosis.
    Neurology. 2017;89:1428.
    PubMed     Text format    


  17. THORMANN A, Sorensen PS, Koch-Henriksen N, Laursen B, et al
    Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality.
    Neurology. 2017 Sep 20. pii: 10.1212/WNL.0000000000004508.
    PubMed     Text format     Abstract available


  18. PLAVINA T, Muralidharan KK, Kuesters G, Mikol D, et al
    Reversibility of the effects of natalizumab on peripheral immune cell dynamics in MS patients.
    Neurology. 2017 Sep 15. pii: 10.1212/WNL.0000000000004485.
    PubMed     Text format     Abstract available


  19. MARRIE RA, Beck CA
    Preventing multiple sclerosis: To (take) vitamin D or not to (take) vitamin D?
    Neurology. 2017 Sep 13. pii: 10.1212/WNL.0000000000004506.
    PubMed     Text format    


  20. FILLI L, Zorner B, Killeen T, Linnebank M, et al
    Author response: Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis.
    Neurology. 2017;89:1200.
    PubMed     Text format    


  21. DAVIS FA
    Letter re: Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis.
    Neurology. 2017;89:1199.
    PubMed     Text format    


  22. COLES AJ, Cohen JA, Fox EJ, Giovannoni G, et al
    Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.
    Neurology. 2017;89:1117-1126.
    PubMed     Text format     Abstract available


  23. HAVRDOVA E, Arnold DL, Cohen JA, Hartung HP, et al
    Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy.
    Neurology. 2017;89:1107-1116.
    PubMed     Text format     Abstract available


  24. LORSCHEIDER J, Jokubaitis VG, Spelman T, Izquierdo G, et al
    Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS.
    Neurology. 2017;89:1050-1059.
    PubMed     Text format     Abstract available


    August 2017
  25. LANGER-GOULD A, Wu J, Lucas R, Smith J, et al
    Epstein-Barr virus, cytomegalovirus, and multiple sclerosis susceptibility: A multiethnic study.
    Neurology. 2017 Aug 30. pii: 10.1212/WNL.0000000000004412.
    PubMed     Text format     Abstract available


  26. HENNES EM, Baumann M, Schanda K, Anlar B, et al
    Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome.
    Neurology. 2017;89:900-908.
    PubMed     Text format     Abstract available


  27. ROSSI S, Studer V, Motta C, Polidoro S, et al
    Neuroinflammation drives anxiety and depression in relapsing-remitting multiple sclerosis.
    Neurology. 2017 Aug 25. pii: 10.1212/WNL.0000000000004411.
    PubMed     Text format     Abstract available


  28. KOCH-HENRIKSEN N, Lauer K
    Dietary sodium intake: An etiologic dead end in multiple sclerosis.
    Neurology. 2017 Aug 25. pii: 10.1212/WNL.0000000000004426.
    PubMed     Text format    


  29. CORTESE M, Yuan C, Chitnis T, Ascherio A, et al
    No association between dietary sodium intake and the risk of multiple sclerosis.
    Neurology. 2017 Aug 25. pii: 10.1212/WNL.0000000000004417.
    PubMed     Text format     Abstract available


  30. WIENDL H, Bourdette D, Ciccarelli O
    Can immune reprogramming with alemtuzumab induce permanent remission in multiple sclerosis?
    Neurology. 2017 Aug 23. pii: 10.1212/WNL.0000000000004381.
    PubMed     Text format    


  31. DE MEO E, Moiola L, Ghezzi A, Veggiotti P, et al
    MRI substrates of sustained attention system and cognitive impairment in pediatric MS patients.
    Neurology. 2017 Aug 18. pii: 10.1212/WNL.0000000000004388.
    PubMed     Text format     Abstract available



  32. Escalation therapy for multiple sclerosis in Austria: Analysis of gender differences in the nationwide registry.
    Neurology. 2017;89:752.
    PubMed     Text format    


    July 2017
  33. NIELSEN NM, Munger KL, Stenager E, Ascherio A, et al
    Author response: Neonatal vitamin D status and risk of multiple sclerosis: A population-based case-control study.
    Neurology. 2017;89:411.
    PubMed     Text format    


  34. XIA Z, Cheng Q, Li J
    Letter re: Neonatal vitamin D status and risk of multiple sclerosis: A population-based case-control study.
    Neurology. 2017;89:410-411.
    PubMed     Text format    


  35. ZARGHAMI A
    Letter re: Neonatal vitamin D status and risk of multiple sclerosis: A population-based case-control study.
    Neurology. 2017;89:410.
    PubMed     Text format    


  36. MARANZANO J, Rudko DA, Nakamura K, Cook S, et al
    MRI evidence of acute inflammation in leukocortical lesions of patients with early multiple sclerosis.
    Neurology. 2017 Jul 19. pii: 10.1212/WNL.0000000000004227.
    PubMed     Text format     Abstract available


  37. HACOHEN Y, Mankad K, Chong WK, Barkhof F, et al
    Diagnostic algorithm for relapsing acquired demyelinating syndromes in children.
    Neurology. 2017;89:269-278.
    PubMed     Text format     Abstract available


  38. LANGER-GOULD A, Smith JB, Hellwig K, Gonzales E, et al
    Breastfeeding, ovulatory years, and risk of multiple sclerosis.
    Neurology. 2017 Jul 12. pii: 10.1212/WNL.0000000000004207.
    PubMed     Text format     Abstract available



  39. Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis.
    Neurology. 2017;89:215.
    PubMed     Text format    


  40. BURKILL S, Montgomery S, Hajiebrahimi M, Hillert J, et al
    Mortality trends for multiple sclerosis patients in Sweden from 1968 to 2012.
    Neurology. 2017 Jul 7. pii: 10.1212/WNL.0000000000004216.
    PubMed     Text format     Abstract available


    June 2017
  41. DE JONG HJI, Kingwell E, Shirani A, Cohen Tervaert JW, et al
    Evaluating the safety of beta-interferons in MS: A series of nested case-control studies.
    Neurology. 2017;88:2310-2320.
    PubMed     Text format     Abstract available


    May 2017
  42. BATISTA S, Alves C, d'Almeida OC, Afonso A, et al
    Disconnection as a mechanism for social cognition impairment in multiple sclerosis.
    Neurology. 2017 May 31. pii: 10.1212/WNL.0000000000004060.
    PubMed     Text format     Abstract available


  43. SOLOMON AJ, Weinshenker BG
    Author response: The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study.
    Neurology. 2017;88:2067-2068.
    PubMed     Text format    


  44. DALLA COSTA G, Martinelli V, Comi G
    Letter re: The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study.
    Neurology. 2017;88:2067.
    PubMed     Text format    


  45. ESHAGHI A, Ciccarelli O
    Author response: Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest.
    Neurology. 2017;88:1875.
    PubMed     Text format    


  46. AVASARALA J
    Letter re: Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest.
    Neurology. 2017;88:1875.
    PubMed     Text format    


  47. MEIJER KA, Eijlers AJC, Douw L, Uitdehaag BMJ, et al
    Increased connectivity of hub networks and cognitive impairment in multiple sclerosis.
    Neurology. 2017 May 3. pii: 10.1212/WNL.0000000000003982.
    PubMed     Text format     Abstract available


    April 2017
  48. SORMANI MP, Muraro PA, Schiavetti I, Signori A, et al
    Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis.
    Neurology. 2017 Apr 28. pii: 10.1212/WNL.0000000000003987.
    PubMed     Text format     Abstract available


  49. GIANFRANCESCO MA, Stridh P, Rhead B, Shao X, et al
    Evidence for a causal relationship between low vitamin D, high BMI, and pediatric-onset MS.
    Neurology. 2017;88:1623-1629.
    PubMed     Text format     Abstract available


    March 2017
  50. LANDI D, De Rossi N, Zagaglia S, Scarpazza C, et al
    No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML.
    Neurology. 2017;88:1144-1152.
    PubMed     Text format     Abstract available


  51. MARRIE RA, Salter A, Tyry T, Cutter GR, et al
    High hypothetical interest in physician-assisted death in multiple sclerosis.
    Neurology. 2017 Mar 15. pii: 10.1212/WNL.0000000000003831.
    PubMed     Text format     Abstract available


  52. ABSINTA M, Cortese IC, Vuolo L, Nair G, et al
    Leptomeningeal gadolinium enhancement across the spectrum of chronic neuroinflammatory diseases.
    Neurology. 2017 Mar 10. pii: 10.1212/WNL.0000000000003820.
    PubMed     Text format     Abstract available


    February 2017
  53. NASH RA, Hutton GJ, Racke MK, Popat U, et al
    High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS.
    Neurology. 2017;88:842-852.
    PubMed     Text format     Abstract available


  54. KUHLE J, Nourbakhsh B, Grant D, Morant S, et al
    Serum neurofilament is associated with progression of brain atrophy and disability in early MS.
    Neurology. 2017;88:826-831.
    PubMed     Text format     Abstract available


  55. SIDHOM Y, Maillart E, Tezenas du Montcel S, Kacem I, et al
    Fast multiple sclerosis progression in North Africans: Both genetics and environment matter.
    Neurology. 2017 Feb 24. pii: 10.1212/WNL.0000000000003762.
    PubMed     Text format     Abstract available


  56. MOWRY EM, McArthur JC
    PML in natalizumab-treated multiple sclerosis: Modeling errors and risk miscalculations.
    Neurology. 2017 Feb 22. pii: 10.1212/WNL.0000000000003749.
    PubMed     Text format    


  57. EIJLERS AJ, Meijer KA, Wassenaar TM, Steenwijk MD, et al
    Increased default-mode network centrality in cognitively impaired multiple sclerosis patients.
    Neurology. 2017 Feb 8. pii: 10.1212/WNL.0000000000003689.
    PubMed     Text format     Abstract available


  58. BARTON J, Hardy TA, Riminton S, Reddel SW, et al
    Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab.
    Neurology. 2017 Feb 8. pii: 10.1212/WNL.0000000000003694.
    PubMed     Text format    


  59. BODINI B, Calabresi PA
    From neurofilament research to multiple sclerosis clinical practice: Where do we stand?
    Neurology. 2017 Feb 1. pii: 10.1212/WNL.0000000000003676.
    PubMed     Text format    


  60. FILLI L, Zorner B, Kapitza S, Reuter K, et al
    Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis.
    Neurology. 2017 Feb 1. pii: 10.1212/WNL.0000000000003656.
    PubMed     Text format     Abstract available


  61. BENNETT SE
    Fampridine: Long-term benefits in walking in multiple sclerosis.
    Neurology. 2017 Feb 1. pii: 10.1212/WNL.0000000000003677.
    PubMed     Text format    


    January 2017
  62. MAAROUF A, Audoin B, Pariollaud F, Gherib S, et al
    Increased total sodium concentration in gray matter better explains cognition than atrophy in MS.
    Neurology. 2017;88:289-295.
    PubMed     Text format     Abstract available


  63. BARGIELA D, Bianchi MT, Westover MB, Chibnik LB, et al
    Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis.
    Neurology. 2017 Jan 13. pii: 10.1212/WNL.0000000000003612.
    PubMed     Text format     Abstract available


  64. BUTTON J, Al-Louzi O, Lang A, Bhargava P, et al
    Disease-modifying therapies modulate retinal atrophy in multiple sclerosis: A retrospective study.
    Neurology. 2017 Jan 11. pii: 10.1212/WNL.0000000000003582.
    PubMed     Text format     Abstract available


    December 2016
  65. ROCCA MA, Battaglini M, Benedict RH, De Stefano N, et al
    Brain MRI atrophy quantification in MS: From methods to clinical application.
    Neurology. 2016 Dec 16. pii: 10.1212/WNL.0000000000003542.
    PubMed     Text format     Abstract available


    November 2016
  66. NIELSEN NM, Munger KL, Koch-Henriksen N, Hougaard DM, et al
    Neonatal vitamin D status and risk of multiple sclerosis: A population-based case-control study.
    Neurology. 2016 Nov 30. pii: 10.1212/WNL.0000000000003454.
    PubMed     Text format     Abstract available


  67. TENSER RB, Truini A, Cruccu G
    A dual concurrent mechanism explains trigeminal neuralgia in patients with multiple sclerosis.
    Neurology. 2016;87:2385-2386.
    PubMed     Text format    



  68. Pediatric multiple sclerosis: The 2015 Sydney Carter Award Lecture.
    Neurology. 2016;87:2284.
    PubMed     Text format    


  69. BEADNALL HN, Gill AJ, Riminton S, Barnett MH, et al
    Virus-related Merkel cell carcinoma complicating fingolimod treatment for multiple sclerosis.
    Neurology. 2016 Nov 16. pii: 10.1212/WNL.0000000000003434.
    PubMed     Text format    



  70. Pediatric multiple sclerosis: Conventional first-line treatment and general management.
    Neurology. 2016;87:2068.
    PubMed     Text format    


  71. ESHAGHI A, Wottschel V, Cortese R, Calabrese M, et al
    Gray matter MRI differentiates neuromyelitis optica from multiple sclerosis using random forest.
    Neurology. 2016 Nov 2. pii: 10.1212/WNL.0000000000003395.
    PubMed     Text format     Abstract available


    October 2016
  72. BOURDETTE D
    Rituximab for treating multiple sclerosis: Off-label but on target.
    Neurology. 2016 Oct 19. pii: 10.1212/WNL.0000000000003345.
    PubMed     Text format    


  73. SALZER J, Svenningsson R, Alping P, Novakova L, et al
    Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.
    Neurology. 2016 Oct 19. pii: 10.1212/WNL.0000000000003331.
    PubMed     Text format     Abstract available


  74. GIOVANNONI G, Cohen JA, Coles AJ, Hartung HP, et al
    Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients.
    Neurology. 2016 Oct 12. pii: 10.1212/WNL.0000000000003319.
    PubMed     Text format     Abstract available


    September 2016
  75. DORANS KS, Massa J, Chitnis T, Ascherio A, et al
    Physical activity and the incidence of multiple sclerosis.
    Neurology. 2016 Sep 28. pii: 10.1212/WNL.0000000000003260.
    PubMed     Text format     Abstract available


  76. KANTOR D, Sotirchos ES, Calabresi PA
    Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis.
    Neurology. 2016;87:1424.
    PubMed     Text format    


  77. COTTER J, Firth J, Enzinger C, Kontopantelis E, et al
    Social cognition in multiple sclerosis: A systematic review and meta-analysis.
    Neurology. 2016 Sep 21. pii: 10.1212/WNL.0000000000003236.
    PubMed     Text format     Abstract available


  78. KELLY DM, Kelleher EM, O'Shea A, Sweeney B, et al
    Teaching Video NeuroImages: Primary writing tremor: Lessons from a patient with multiple sclerosis.
    Neurology. 2016;87:e131.
    PubMed     Text format    


  79. BOVE R, White CC, Fitzgerald KC, Chitnis T, et al
    Hormone therapy use and physical quality of life in postmenopausal women with multiple sclerosis.
    Neurology. 2016 Sep 7. pii: 10.1212/WNL.0000000000003176.
    PubMed     Text format     Abstract available


  80. VOSKUHL R, Patti F
    Hormone replacement in menopausal women with multiple sclerosis: Looking back, thinking forward.
    Neurology. 2016 Sep 7. pii: 10.1212/WNL.0000000000003189.
    PubMed     Text format    


  81. ARNOLD DL, Fisher E, Brinar VV, Cohen JA, et al
    Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon beta-1a in MS.
    Neurology. 2016 Sep 2. pii: 10.1212/WNL.0000000000003169.
    PubMed     Text format     Abstract available


    August 2016
  82. SOLOMON AJ, Bourdette DN, Cross AH, Applebee A, et al
    The contemporary spectrum of multiple sclerosis misdiagnosis: A multicenter study.
    Neurology. 2016 Aug 31. pii: 10.1212/WNL.0000000000003152.
    PubMed     Text format     Abstract available


  83. GHEZZI A, Amato MP, Makhani N, Shreiner T, et al
    Pediatric multiple sclerosis: Conventional first-line treatment and general management.
    Neurology. 2016;87.
    PubMed     Text format     Abstract available


  84. BANWELL B, Arnold DL, Tillema JM, Rocca MA, et al
    MRI in the evaluation of pediatric multiple sclerosis.
    Neurology. 2016;87.
    PubMed     Text format     Abstract available


  85. AMATO MP, Krupp LB, Charvet LE, Penner I, et al
    Pediatric multiple sclerosis: Cognition and mood.
    Neurology. 2016;87.
    PubMed     Text format     Abstract available


  86. WALDMAN A, Ness J, Pohl D, Simone IL, et al
    Pediatric multiple sclerosis: Clinical features and outcome.
    Neurology. 2016;87.
    PubMed     Text format     Abstract available


  87. HINTZEN RQ, Dale RC, Neuteboom RF, Mar S, et al
    Pediatric acquired CNS demyelinating syndromes: Features associated with multiple sclerosis.
    Neurology. 2016;87.
    PubMed     Text format     Abstract available


  88. KRUPP LB, Rintell D, Charvet LE, Milazzo M, et al
    Pediatric multiple sclerosis: Perspectives from adolescents and their families.
    Neurology. 2016;87.
    PubMed     Text format     Abstract available


  89. CHITNIS T, Ghezzi A, Bajer-Kornek B, Boyko A, et al
    Pediatric multiple sclerosis: Escalation and emerging treatments.
    Neurology. 2016;87.
    PubMed     Text format     Abstract available


  90. BANWELL B
    Pediatric multiple sclerosis: The 2015 Sydney Carter Award Lecture.
    Neurology. 2016;87:822-6.
    PubMed     Text format    


  91. KHALIL M, Salzer J
    CSF neurofilament light: A universal risk biomarker in multiple sclerosis?
    Neurology. 2016 Aug 12. pii: 10.1212/WNL.0000000000003107.
    PubMed     Text format    



  92. Journal Club: Effect of comorbidity on mortality in multiple sclerosis.
    Neurology. 2016;87:646.
    PubMed     Text format    


  93. JONES DE, Sutliff MH, Halper J, Armstrong MJ, et al
    Summary of comprehensive systematic review: Rehabilitation in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2016;87:646.
    PubMed     Text format    


    July 2016
  94. PURCHIARONI F, Salvetti M, Buscarinu MC, Annibale B, et al
    Eosinophilic gastroenteritis in a woman with multiple sclerosis on dimethyl fumarate.
    Neurology. 2016 Jul 27. pii: 10.1212/WNL.0000000000003045.
    PubMed     Text format    


  95. BENOIT A, Durand-Dubief F, Amato MP, Portaccio E, et al
    History of multiple sclerosis in 2 successive pregnancies: A French and Italian cohort.
    Neurology. 2016 Jul 27. pii: 10.1212/WNL.0000000000003036.
    PubMed     Text format     Abstract available


  96. GILMORE W, Airas L
    Successive pregnancies in multiple sclerosis.
    Neurology. 2016 Jul 27. pii: 10.1212/WNL.0000000000003039.
    PubMed     Text format    


  97. GOLAN D, Miller A, Sotirchos ES, Bhargava P, et al
    Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis.
    Neurology. 2016;87:446.
    PubMed     Text format    


  98. AVASARALA J, Sotirchos ES, Bhargava P, Calabresi PA, et al
    Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis.
    Neurology. 2016;87:445-6.
    PubMed     Text format    


  99. PREZIOSA P, Comi G, Filippi M
    Optic neuritis in multiple sclerosis: Looking from a patient's eyes.
    Neurology. 2016;87:338-9.
    PubMed     Text format    


  100. MILLER AE, Pelletier D
    Multiple sclerosis: Rapid diagnosis or right diagnosis?
    Neurology. 2016 Jul 15. pii: 10.1212/WNL.0000000000002994.
    PubMed     Text format    


  101. BROWNLEE WJ, Swanton JK, Miszkiel KA, Miller DH, et al
    Should the symptomatic region be included in dissemination in space in MRI criteria for MS?
    Neurology. 2016 Jul 15. pii: 10.1212/WNL.0000000000002975.
    PubMed     Text format     Abstract available


    June 2016
  102. WANG G, Marrie RA, Salter AR, Fox R, et al
    Health insurance affects the use of disease-modifying therapy in multiple sclerosis.
    Neurology. 2016 Jun 29. pii: 10.1212/WNL.0000000000002887.
    PubMed     Text format     Abstract available


  103. LEHMANN-HORN K, Penkert H, Grein P, Leppmeier U, et al
    PML during dimethyl fumarate treatment of multiple sclerosis: How does lymphopenia matter?
    Neurology. 2016 Jun 24. pii: 10.1212/WNL.0000000000002900.
    PubMed     Text format    


  104. DE FLON P, Gunnarsson M, Laurell K, Soderstrom L, et al
    Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab.
    Neurology. 2016 Jun 17. pii: 10.1212/WNL.0000000000002832.
    PubMed     Text format     Abstract available


    May 2016
  105. KARAMYAN A, Sellner J
    Journal Club: Effect of comorbidity on mortality in multiple sclerosis.
    Neurology. 2016;86:e228-30.
    PubMed     Text format    


  106. SENA A, Capela C, Ferret-Sena V, Munger KL, et al
    No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT.
    Neurology. 2016;86:2026.
    PubMed     Text format    


  107. BUTTMANN M, Seuffert L, Mader U, Toyka KV, et al
    Malignancies after mitoxantrone for multiple sclerosis: A retrospective cohort study.
    Neurology. 2016 May 11. pii: 10.1212/WNL.0000000000002745.
    PubMed     Text format     Abstract available


  108. TRUINI A, Prosperini L, Calistri V, Fiorelli M, et al
    A dual concurrent mechanism explains trigeminal neuralgia in patients with multiple sclerosis.
    Neurology. 2016 May 4. pii: 10.1212/WNL.0000000000002720.
    PubMed     Text format     Abstract available


    April 2016
  109. SUMOWSKI JF, Rocca MA, Leavitt VM, Meani A, et al
    Brain reserve against physical disability progression over 5 years in multiple sclerosis.
    Neurology. 2016 Apr 27. pii: 10.1212/WNL.0000000000002702.
    PubMed     Text format     Abstract available


  110. DE LOTT LB, Burke JF, Kerber KA, Skolarus LE, et al
    Medicare Part D payments for neurologist-prescribed drugs.
    Neurology. 2016;86:1491-8.
    PubMed     Text format     Abstract available



  111. Quality improvement in neurology: Multiple sclerosis quality measures: Executive summary.
    Neurology. 2016;86:1465.
    PubMed     Text format    


  112. MCDONNELL GV, Bennett A, Rae-Grant A, Bever C, et al
    Quality improvement in neurology: Multiple sclerosis quality measures: Executive summary.
    Neurology. 2016;86:1361.
    PubMed     Text format    


  113. BENNETT A, Rae-Grant A, Bever C
    Author Response.
    Neurology. 2016;86:1361.
    PubMed     Text format    


    March 2016
  114. HODEL J, Darchis C, Outteryck O, Verclytte S, et al
    Punctate pattern: A promising imaging marker for the diagnosis of natalizumab-associated PML.
    Neurology. 2016 Mar 23. pii: 10.1212/WNL.0000000000002586.
    PubMed     Text format     Abstract available


  115. GRANT WB, Riise T
    Multiple sclerosis: A lifestyle disease?
    Neurology. 2016 Mar 9. pii: 10.1212/WNL.0000000000002487.
    PubMed     Text format    


  116. BERRIGAN LI, Fisk JD, Patten SB, Tremlett H, et al
    Health-related quality of life in multiple sclerosis: Direct and indirect effects of comorbidity.
    Neurology. 2016 Mar 9. pii: 10.1212/WNL.0000000000002564.
    PubMed     Text format     Abstract available


  117. MARRIE RA, Patten SB, Tremlett H, Wolfson C, et al
    Sex differences in comorbidity at diagnosis of multiple sclerosis: A population-based study.
    Neurology. 2016 Mar 9. pii: 10.1212/WNL.0000000000002481.
    PubMed     Text format     Abstract available


  118. O'CONNOR P, Comi G, Freedman MS, Miller AE, et al
    Long-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.
    Neurology. 2016;86:920-30.
    PubMed     Text format     Abstract available


  119. ZHANG T, Tremlett H, Leung S, Zhu F, et al
    Examining the effects of comorbidities on disease-modifying therapy use in multiple sclerosis.
    Neurology. 2016 Mar 4. pii: 10.1212/WNL.0000000000002543.
    PubMed     Text format     Abstract available


    February 2016
  120. BARBIN L, Rousseau C, Jousset N, Casey R, et al
    Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.
    Neurology. 2016;86:771-8.
    PubMed     Text format     Abstract available


  121. MARRIE RA, Miller A, Sormani MP, Thompson A, et al
    The challenge of comorbidity in clinical trials for multiple sclerosis.
    Neurology. 2016 Feb 17. pii: 10.1212/WNL.0000000000002471.
    PubMed     Text format     Abstract available


  122. DILOKTHORNSAKUL P, Valuck RJ, Nair KV, Corboy JR, et al
    Multiple sclerosis prevalence in the United States commercially insured population.
    Neurology. 2016 Feb 17. pii: 10.1212/WNL.0000000000002469.
    PubMed     Text format     Abstract available


  123. MARRIE RA, Miller A, Sormani MP, Thompson A, et al
    Recommendations for observational studies of comorbidity in multiple sclerosis.
    Neurology. 2016 Feb 10. pii: 10.1212/WNL.0000000000002474.
    PubMed     Text format     Abstract available


  124. CORTESE I, Ohayon J, Fenton K, Lee CC, et al
    Cutaneous adverse events in multiple sclerosis patients treated with daclizumab.
    Neurology. 2016 Feb 3. pii: 10.1212/WNL.0000000000002417.
    PubMed     Text format     Abstract available


  125. HAN C, Huang J, Waxman SG
    Sodium channel Nav1.8: Emerging links to human disease.
    Neurology. 2016;86:473-83.
    PubMed     Text format     Abstract available


    January 2016
  126. SHEIKH Z, Jain S, Hillen M
    Acute retinal necrosis in multiple sclerosis: A neuroimmunologic challenge!
    Neurology. 2016 Jan 29. pii: 10.1212/WNL.0000000000002450.
    PubMed     Text format    


  127. BOURRE B, Gueudry J, Lefaucheur R, Borden A, et al
    Progressive outer retinal necrosis in a multiple sclerosis patient on natalizumab.
    Neurology. 2016;86:312-3.
    PubMed     Text format    


  128. LINCOLN MR, Schneider R, Hohol M
    Clinical Reasoning: A 34-year-old man with headache, diplopia, and hemiparesis.
    Neurology. 2016;86:e24-8.
    PubMed     Text format    


  129. CHITNIS T, Ness J, Krupp L, Waubant E, et al
    Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report.
    Neurology. 2016;86:245-52.
    PubMed     Text format     Abstract available


  130. BODINI B, Chard D, Altmann DR, Tozer D, et al
    White and gray matter damage in primary progressive MS: The chicken or the egg?
    Neurology. 2016;86:170-6.
    PubMed     Text format     Abstract available


  131. WAXMAN SG, Kantarci O
    The cerebellar channelopathy of multiple sclerosis.
    Neurology. 2016 Jan 6. pii: 10.1212/WNL.0000000000002338.
    PubMed     Text format    


  132. ROOSTAEI T, Sadaghiani S, Park MT, Mashhadi R, et al
    Channelopathy-related SCN10A gene variants predict cerebellar dysfunction in multiple sclerosis.
    Neurology. 2016 Jan 6. pii: 10.1212/WNL.0000000000002326.
    PubMed     Text format     Abstract available


    December 2015
  133. SOTIRCHOS ES, Bhargava P, Eckstein C, Van Haren K, et al
    Safety and immunologic effects of high- vs low-dose cholecalciferol in multiple sclerosis.
    Neurology. 2015 Dec 30. pii: 10.1212/WNL.0000000000002316.
    PubMed     Text format     Abstract available


  134. LIEBERMAN LA, Zeng W, Singh C, Wang W, et al
    CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients.
    Neurology. 2015 Dec 30. pii: 10.1212/WNL.0000000000002314.
    PubMed     Text format     Abstract available


  135. MARRIE RA, Fisk JD, Tremlett H, Wolfson C, et al
    Differences in the burden of psychiatric comorbidity in MS vs the general population.
    Neurology. 2015;85:1972-9.
    PubMed     Text format     Abstract available


    November 2015
  136. HASELKORN JK, Hughes C, Rae-Grant A, Henson LJ, et al
    Summary of comprehensive systematic review: Rehabilitation in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
    Neurology. 2015;85:1896-903.
    PubMed     Text format     Abstract available



  137. The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
    Neurology. 2015;85:1728.
    PubMed     Text format    


  138. TISCHNER JR, Hartung DM, Bourdette DN, Whitham RH, et al
    The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
    Neurology. 2015;85:1727-8.
    PubMed     Text format    


  139. RITTENHOUSE BE
    The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail?
    Neurology. 2015;85:1727-8.
    PubMed     Text format    


  140. HARTUNG DM, Bourdette DN, Ahmed S, Whitham RH, et al
    Author response.
    Neurology. 2015;85:1728.
    PubMed     Text format    


  141. RITTENHOUSE BE
    The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: too big to fail?
    Neurology. 2015;85:1727-8.
    PubMed     Text format    


  142. HARTUNG DM, Bourdette DN, Whitham RH
    Author response.
    Neurology. 2015;85:1727.
    PubMed     Text format    


  143. DE STEFANO N, Stromillo ML, Giorgio A, Battaglini M, et al
    Long-term assessment of no evidence of disease activity in relapsing-remitting MS.
    Neurology. 2015;85:1722-3.
    PubMed     Text format    


  144. DEBS R, Maillart E, Fahed R, Papeix C, et al
    Extensive brain demyelinating lesions under natalizumab: The role of anti-natalizumab antibodies.
    Neurology. 2015;85:1630-2.
    PubMed     Text format    


    October 2015
  145. LOUAPRE C, Govindarajan ST, Gianni C, Langkammer C, et al
    Beyond focal cortical lesions in MS: An in vivo quantitative and spatial imaging study at 7T.
    Neurology. 2015 Oct 14. pii: 10.1212/WNL.0000000000002106.
    PubMed     Text format     Abstract available



  146. Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis.
    Neurology. 2015;85:1355.
    PubMed     Text format    


  147. MUNGER KL, Fitzgerald KC, Freedman MS, Hartung HP, et al
    No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT.
    Neurology. 2015 Oct 9. pii: 10.1212/WNL.0000000000002099.
    PubMed     Text format     Abstract available


  148. LAURSEN JH, Sondergaard HB, Sorensen PS, Sellebjerg F, et al
    Association between age at onset of multiple sclerosis and vitamin D level-related factors.
    Neurology. 2015 Oct 7. pii: 10.1212/WNL.0000000000002075.
    PubMed     Text format     Abstract available


  149. BOVE R, Malik MT, Diaz-Cruz C, Chua A, et al
    The 2D:4D ratio, a proxy for prenatal androgen levels, differs in men with and without MS.
    Neurology. 2015;85:1209-13.
    PubMed     Text format     Abstract available


  150. LUCAS RM, Banwell B
    Do prenatal sex hormones modulate MS risk?
    Neurology. 2015;85:1193-4.
    PubMed     Text format    


    September 2015
  151. LABINER DM
    William A. Sibley, MD (1925-2015).
    Neurology. 2015;85:1016.
    PubMed     Text format    



  152. Meningeal inflammation in multiple sclerosis: The key to the origin of cortical lesions?
    Neurology. 2015;85:1010.
    PubMed     Text format    


  153. RAE-GRANT A, Bennett A, Sanders AE, Phipps M, et al
    Quality improvement in neurology: Multiple sclerosis quality measures: Executive summary.
    Neurology. 2015 Sep 2. pii: 10.1212/WNL.0000000000001965.
    PubMed     Text format    


    August 2015
  154. PARDINI M, Yaldizli O, Sethi V, Muhlert N, et al
    Motor network efficiency and disability in multiple sclerosis.
    Neurology. 2015 Aug 28. pii: 10.1212/WNL.0000000000001970.
    PubMed     Text format     Abstract available


  155. SORMANI MP, Evangelou N
    New imaging language skills required in MS.
    Neurology. 2015 Aug 28. pii: 10.1212/WNL.0000000000001978.
    PubMed     Text format    


  156. HUANG D
    Disseminated cryptococcosis in a patient with multiple sclerosis treated with fingolimod.
    Neurology. 2015 Aug 19. pii: 10.1212/WNL.0000000000001929.
    PubMed     Text format    


  157. RINGELSTEIN M, Albrecht P, Kleffner I, Buhn B, et al
    Retinal pathology in Susac syndrome detected by spectral-domain optical coherence tomography.
    Neurology. 2015;85:610-8.
    PubMed     Text format     Abstract available


  158. ROCCA MA, Filippi M, Deiva K
    Promoting physical activity to control multiple sclerosis from childhood.
    Neurology. 2015 Aug 12. pii: 10.1212/WNL.0000000000001941.
    PubMed     Text format    


  159. GROVER SA, Aubert-Broche B, Fetco D, Collins DL, et al
    Lower physical activity is associated with higher disease burden in pediatric multiple sclerosis.
    Neurology. 2015 Aug 12. pii: 10.1212/WNL.0000000000001939.
    PubMed     Text format     Abstract available


    July 2015
  160. HACOHEN Y, Zuberi S, Vincent A, Crow YJ, et al
    Neuromyelitis optica in a child with Aicardi-Goutieres syndrome.
    Neurology. 2015;85:381-3.
    PubMed     Text format    


  161. NOVOTNA M, Paz Soldan MM, Abou Zeid N, Kale N, et al
    Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis.
    Neurology. 2015 Jul 24. pii: 10.1212/WNL.0000000000001856.
    PubMed     Text format     Abstract available


  162. WINGERCHUK DM, Banwell B, Bennett JL, Cabre P, et al
    International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.
    Neurology. 2015;85:177-89.
    PubMed     Text format     Abstract available


  163. KISTER I, Paul F
    Pushing the boundaries of neuromyelitis optica: does antibody make the disease?
    Neurology. 2015;85:118-9.
    PubMed     Text format    


  164. KAPPOS L, Radue EW, Comi G, Montalban X, et al
    Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS.
    Neurology. 2015;85:29-39.
    PubMed     Text format     Abstract available


  165. TRANAH GJ, Santaniello A, Caillier SJ, D'Alfonso S, et al
    Mitochondrial DNA sequence variation in multiple sclerosis.
    Neurology. 2015 Jul 1. pii: 10.1212/WNL.0000000000001744.
    PubMed     Text format     Abstract available


    June 2015
  166. DAAMS M, Steenwijk MD, Wattjes MP, Geurts JJ, et al
    Unraveling the neuroimaging predictors for motor dysfunction in long-standing multiple sclerosis.
    Neurology. 2015 Jun 26. pii: 10.1212/WNL.0000000000001756.
    PubMed     Text format     Abstract available


  167. ROVIRA A, Wiggermann V, Rauscher A
    Trajectories of subcortical iron accumulation in MS.
    Neurology. 2015;84:2388-9.
    PubMed     Text format    


  168. PFENDER N, Jelcic I, Linnebank M, Schwarz U, et al
    Reactivation of herpesvirus under fingolimod: A case of severe herpes simplex encephalitis.
    Neurology. 2015;84:2377-8.
    PubMed     Text format    


    May 2015
  169. MARRIE RA, Elliott L, Marriott J, Cossoy M, et al
    Effect of comorbidity on mortality in multiple sclerosis.
    Neurology. 2015 May 27. pii: 10.1212/WNL.0000000000001718.
    PubMed     Text format     Abstract available


  170. BROWN MG
    Cost of disease-modifying therapies for multiple sclerosis.
    Neurology. 2015;84:e181-5.
    PubMed     Text format    


  171. GILBERT GJ
    A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis.
    Neurology. 2015;84:2201.
    PubMed     Text format    


  172. VAN TASSEL SH, Gupta MP, Orlin A, Nealon NM, et al
    Progressive outer retinal necrosis in a multiple sclerosis patient on natalizumab.
    Neurology. 2015;84:2198-9.
    PubMed     Text format    


  173. MURRAY TJ, Brown MG
    Escalating MS drug costs in the US: Puzzling, troubling, and suspicious.
    Neurology. 2015;84:2105-6.
    PubMed     Text format    


  174. KHALIL M, Langkammer C, Pichler A, Pinter D, et al
    Dynamics of brain iron levels in multiple sclerosis: A longitudinal 3T MRI study.
    Neurology. 2015 May 15. pii: 10.1212/WNL.0000000000001679.
    PubMed     Text format     Abstract available


    April 2015
  175. WEINSHENKER BG, Barron G, Behne JM, Bennett JL, et al
    Challenges and opportunities in designing clinical trials for neuromyelitis optica.
    Neurology. 2015;84:1805-15.
    PubMed     Text format     Abstract available


  176. LIU Y, Wang J, Daams M, Weiler F, et al
    Differential patterns of spinal cord and brain atrophy in NMO and MS.
    Neurology. 2015;84:1465-72.
    PubMed     Text format     Abstract available


    March 2015
  177. MURARO PA
    Andiamo! Moving forward with autologous hematopoietic transplantation for highly active MS.
    Neurology. 2015;84:968-9.
    PubMed     Text format    


  178. LUBLIN FD
    Author response.
    Neurology. 2015;84:963.
    PubMed     Text format    


    February 2015
  179. KIM HJ, Paul F, Lana-Peixoto MA, Tenembaum S, et al
    MRI characteristics of neuromyelitis optica spectrum disorder: An international update.
    Neurology. 2015 Feb 18. pii: 10.1212/WNL.0000000000001367.
    PubMed     Text format     Abstract available


  180. MILLER DH, Fox RJ, Phillips JT, Hutchinson M, et al
    Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study.
    Neurology. 2015 Feb 13. pii: 10.1212/WNL.0000000000001360.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: